clinical trial · NCT03866798
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Octapharma·phase4·terminated·n = 6
Chronic Immune ThrombocytopeniaPanzyga
brief summary
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
started
Jan 21, 2020
primary completion
Sep 19, 2023
completion
May 17, 2024
last updated
Sep 24, 2024
official title
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol